EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs

Kazuhiro Murai iD, Hayato Hikita, Ryoko Yamada, Yuki Nishimura, Masanori Miyazaki, Hisashi Ishida, Atsushi Hosui, Ryotaro Sakamori iD, Nobuyuki Tatsumi, Kazuyoshi Ohkawa, Yoshinori Doi, Takatoshi Nawa und 25 weitere

Hepatology Research · 2025-09 · 55 (9) · 1228-1238

DOI: 10.1111/hepr.14225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 16.06.2025. Verfasst von Kazuhiro Murai und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Nucleos(t)ide analogs (NUCs) are used in the treatment of chronic hepatitis B (CHB). It is still uncertain whether the risk of incident hepatocellular carcinoma (HCC) continues beyond 5 or 10 years after the initiation of NUC treatment. We aimed to elucidate this in CHB patients receiving long‐term NUC treatment.

Methods

This was a multicenter, observational study that included patients who began NUC treatment between July 2000 and March 2019; patients were retrospectively enrolled up to March 2019 and followed up until August 2024.

Results

Among 737 CHB patients (156 with cirrhosis) who started NUC treatment, 147 developed HCC during a median follow‐up period of 144.2 months. The 5‐, 10‐, and 15‐year cumulative HCC rates were 11.2%, 18.4%, and 23.1%, respectively. Independent risk factors for subsequent HCC occurrence included older age, male sex, cirrhosis, low platelet count, low ALT levels, and high γ ‐GTP levels at NUC initiation. After 5 years, the risk factors were cirrhosis, high γ ‐GTP levels, and high AFP levels, whereas after 10 years, they were cirrhosis and diabetes. Landmark analysis revealed that the 5‐year cumulative HCC incidence was 8.1% at 5 years and 5.8% at 10 years after NUC initiation. In noncirrhotic patients, cumulative HCC incidence at 5 years was 5.8%, whereas 5‐year cumulative incidences starting at 5 and 10 years were 4.1% and 4.8%, respectively, remaining stable over time.

Conclusion

The risk of HCC persists long after NUC initiation. In noncirrhotic patients, the risk remains stable more than 10 years after NUC treatment initiation.

Schlagwörter

Stichwörter der Autor:innen

CHBHBVHCCNUCcirrhosis

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Medical Innovation, The University of Osaka Hospital, Suita, Japan.
  • Department of Gastroenterology, Osaka Keisatsu Hospital, Suita, Japan.
  • Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Japan.
  • Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai, Japan.
  • Department of Gastroenterology and Hepatology, NHO Osaka National Hospital, Osaka, Japan.

ORCID-Profile: Kazuhiro Murai, Ryotaro Sakamori, Kengo Matsumoto, Shinji Kuriki, Yuki Tahata, Yoshinobu Saito, Takahiro Kodama, Tetsuo Takehara

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Murai, K., Hikita, H., Yamada, R., Nishimura, Y., Miyazaki, M., Ishida, H., Hosui, A., Sakamori, R., Tatsumi, N., Ohkawa, K., Doi, Y., Nawa, T., Egawa, S., Yoshida, Y., Nozaki, Y., Imanaka, K., Nakahara, M., Sakakibara, M., Yakushijin, T., …, & Takehara, T. (2025). The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs. Hepatology Research, 55(9), 1228-1238. https://doi.org/10.1111/hepr.14225

Vancouver

Murai K, Hikita H, Yamada R, Nishimura Y, Miyazaki M, Ishida H, et al. The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs. Hepatology Research. 2025;55(9):1228-1238. doi:10.1111/hepr.14225

BibTeX
@article{Murai2025,
  author = {Murai, Kazuhiro and Hikita, Hayato and Yamada, Ryoko and Nishimura, Yuki and Miyazaki, Masanori and Ishida, Hisashi and Hosui, Atsushi and Sakamori, Ryotaro and Tatsumi, Nobuyuki and Ohkawa, Kazuyoshi and Doi, Yoshinori and Nawa, Takatoshi and Egawa, Satoshi and Yoshida, Yuichi and Nozaki, Yasutoshi and Imanaka, Kazuho and Nakahara, Masanori and Sakakibara, Mitsuru and Yakushijin, Takayuki and Ogawa, Hiroyuki and Usui, Takeo and Matsumoto, Kengo and Oze, Tsugiko and Kuriki, Shinji and Sometani, Emi and Sung, Jihyun and Shimoda, Akiyoshi and Shigeno, Satoshi and Maesaka, Kazuki and Shirai, Kumiko and Doi, Akira and Tahata, Yuki and Saito, Yoshinobu and Kodama, Takahiro and Tatsumi, Tomohide and Yamada, Tomomi and Takehara, Tetsuo},
  title = {The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs},
  journal = {Hepatology Research},
  year = {2025},
  volume = {55},
  number = {9},
  pages = {1228--1238},
  doi = {10.1111/hepr.14225}
}
Kostenlos starten →